Longitudinal ctDNA monitoring in patients with metastatic uveal melanoma undergoing isolated hepatic perfusion in combination with ipilimumab and nivolumab.

ABSTRACT:

Background

Uveal melanoma (UM) is a rare cancer, which often metastasizes to the liver, leading to a poor prognosis. In the randomized SCANDIUM II trial, patients with metastatic UM received a one-time treatment with isolated hepatic perfusion using high-dose melphalan in combination with systemic immune checkpoint inhibition with ipilimumab (3 mg/kg) and nivolumab (1 mg/kg). In this study, we assessed circulating tumor DNA (ctDNA) in prospectively collected blood samples from all patients in the SCANDIUM II trial to detect residual disease and recurrence as a strategy to evaluate treatment efficacy and predict prognosis.

Patients and methods

We analyzed ctDNA in 128 plasma samples from 18 patients using digital PCR (Oncobit™ PM) targeting GNA11 Q209L (n = 9), GNAQ Q2

SUBMITTER: Kadefors M 

PROVIDER: S-EPMC12682135 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature